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Abstract: Pancreatic ductal adenocarcinoma (PDAC) is a disease with a very unfavorable prognosis. Sur-
gical resection represents the only potentially curative treatment option, but recurrence after complete
resection is almost certain. In an exploratory attempt we here aimed at identifying preoperative plasma
protein biomarkers with the potential to predict early recurrence after resection of PDAC. Peripheral
blood samples from 14 PDAC patients divided into three groups according to their time to tumor recur-
rence after curatively intended resection (early: < 6 months, medium: 6-12 months, late: > 12 months)
underwent targeted proteome analysis. Proteins most strongly discriminating early and late recurrence
were then examined in a number of established PDAC cell lines and their culture supernatants. Finally,
PDAC organoid lines from primary tumors of patients with early and late recurrence were analyzed for
confirmation and validation of results. In total, 23 proteins showed differential abundance in periopera-
tive plasma from PDAC patients with early recurrence when compared to patients with late recurrence.
Following confirmation of expression on a transcriptional and translational level in PDAC cell lines we
further focused on three upregulated (MAEA, NT5E, AZU1) and two downregulated proteins (ATP6AP2,
MICA). Increased expression of NT5E was confirmed in a subset of PDAC organoid cultures from tumors
with early recurrence. MICA expression was heterogeneous and ATP6AP2 levels were very similar in
both organoids from early and late recurrent tumors. Most strikingly, we observed high MAEA expression
in all tested PDAC (n = 7) compared to a non-cancer ductal organoid line. MAEA also demonstrated
potential to discriminate early recurrence from late recurrence PDAC organoids. Our study suggests
that identification of plasma protein biomarkers released by tumor cells may be feasible and of value to
predict the clinical course of patients. Prediction of recurrence dynamics would help to stratify up-front
resectable PDAC patients for neoadjuvant chemotherapy approaches in an individualized fashion. Here,
MAEA and NT5E were the most promising candidates for further evaluation.
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Plasma biomarkers for prediction 
of early tumor recurrence 
after resection of pancreatic ductal 
adenocarcinoma
Marie‑Claire Rittmann1, Saskia Hussung2,3, Lukas M. Braun1,2, Rhena F. U. Klar2, 
Esther A. Biesel1, Stefan Fichtner‑Feigl1, Ralph Fritsch2,3, Uwe A. Wittel1* & 
Dietrich A. Ruess1 
Pancreatic ductal adenocarcinoma (PDAC) is a disease with a very unfavorable prognosis. Surgical 
resection represents the only potentially curative treatment option, but recurrence after complete 
resection is almost certain. In an exploratory attempt we here aimed at identifying preoperative 
plasma protein biomarkers with the potential to predict early recurrence after resection of PDAC. 
Peripheral blood samples from 14 PDAC patients divided into three groups according to their time 
to tumor recurrence after curatively intended resection (early: < 6 months, medium: 6–12 months, 
late: > 12 months) underwent targeted proteome analysis. Proteins most strongly discriminating 
early and late recurrence were then examined in a number of established PDAC cell lines and their 
culture supernatants. Finally, PDAC organoid lines from primary tumors of patients with early and 
late recurrence were analyzed for confirmation and validation of results. In total, 23 proteins showed 
differential abundance in perioperative plasma from PDAC patients with early recurrence when 
compared to patients with late recurrence. Following confirmation of expression on a transcriptional 
and translational level in PDAC cell lines we further focused on three upregulated (MAEA, NT5E, 
AZU1) and two downregulated proteins (ATP6AP2, MICA). Increased expression of NT5E was 
confirmed in a subset of PDAC organoid cultures from tumors with early recurrence. MICA expression 
was heterogeneous and ATP6AP2 levels were very similar in both organoids from early and late 
recurrent tumors. Most strikingly, we observed high MAEA expression in all tested PDAC (n = 7) 
compared to a non‑cancer ductal organoid line. MAEA also demonstrated potential to discriminate 
early recurrence from late recurrence PDAC organoids. Our study suggests that identification of 
plasma protein biomarkers released by tumor cells may be feasible and of value to predict the clinical 
course of patients. Prediction of recurrence dynamics would help to stratify up‑front resectable PDAC 
patients for neoadjuvant chemotherapy approaches in an individualized fashion. Here, MAEA and 
NT5E were the most promising candidates for further evaluation.
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignant disease of the exocrine pancreas with 
a 5-year survival rate less than 10%1. Rapid disease progression with early metastatic spread and lack of early 
clinical symptoms contribute to the poor prognosis. The only curative therapy for PDAC is surgical resection, 
but only 15 to 20% of all patients are  eligible2. Most patients suffer from locally advanced or metastatic disease at 
the time of diagnosis, which precludes surgical options and limits the estimated overall survival of these patients 
to less than a  year3.
Almost all patients encounter tumor recurrence after histologically complete tumor resection. Adjuvant 
chemotherapy is recommended with modified FOLFIRINOX and has been shown to substantially increase overall 
 survival4. In patients with lower performance status, gemcitabine +  capecitabine5, gemcitabine or 5-fluoruracil 
(5-FU) remains the current standard of  care6,7. Recurrence occurs quite early after tumor resection and despite 
adjuvant chemotherapy 30–50% of patients develop a postoperative tumor relapse within one year after  surgery8. 
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To explain the early postoperative recurrence (up to 6 months after resection), an already disseminated disease is 
likely, which is not detectable macroscopically at the time of diagnosis or operation. Other studies found lymph 
node  metastasis9, perineural  invasion10 and status of resection  margin11 to be strongly associated with early tumor 
recurrence and poor survival outcomes after surgical intervention.
Until today, no biomarker is available to predict prognosis. Even specific and sensitive diagnostic markers 
for early detection of PDAC are limited. However, carbohydrate antigen Ca19-9 is used in clinical practice for 
assessment of PDAC progression and monitoring of disease  activity12. With reliable data on neoadjuvant therapy 
strategies becoming increasingly  available13, it becomes more and more essential to identify preoperatively 
detectable parameters, as patients with resectable tumors with increased risk of early recurrence may benefit 
from other treatment options such as neoadjuvant chemotherapy before surgery.
In this explorative study we aimed at identifying and characterizing plasma biomarkers that may preopera-
tively predict PDAC recurrence after curative resection.
Methods
Study design, data management and ethics statement. Blood and tissue samples as well as clinical 
data were collected after having acquired written informed consent from all patients prior to surgery. The study 
was approved by the Ethics Committee of the University of Freiburg (No. 126/17 and 73/18) and was registered 
in the German Register of Clinical Studies (DRKS-ID: DRKS00023929; date of registration: 12/17/2020). All 
methods were performed in accordance with the Declaration of Helsinki and with all relevant guidelines and 
regulations. Clinical data was continuously documented and analyzed retrospectively. PDAC diagnosis was con-
firmed by routine pathology after resection of pancreatic tumor.
Plasma samples. In total, plasma of 14 patients was used in this study. Plasma samples were pooled on the 
basis of patients’ tumor relapse time (early recurrence: within 6 months after resection, n = 5; medium recur-
rence: within 6–12 months after resection, n = 4; late recurrence: no relapse 12 months after resection, n = 5). 
Plasma of PDAC patients was collected one day prior to planned resection and during resection and was ana-
lyzed. The plasma samples were evaluated by a plasma proteome array for 1012 pre-defined biomarkers in the 
panels cardiometabolic, cardiovascular II + III, cell regulation, development, immune response, inflammation, 
metabolism, neurology, oncology II and organ damage (Olink Bioscience, Uppsala, Sweden). The data were 
normalized using an internal and interplate control to minimize both intra- and inter-assay variation and then 
transformed using a pre-determined correction factor. Pre-processed data are provided in the arbitrary unit nor-
malized protein expression (NPX) on a log2 scale. A high NPX value corresponds to a high protein concentra-
tion and expresses relative quantification between samples, therefore no comparison of absolute levels between 
different proteins can be made.
Cell culture. The pancreatic cancer cell lines PANC-1 (CRL-1469™), MIA PaCa-2 (CRM-CRL-1420™), 
Capan-2 (HTB-80™) and HPAF-II (CRL-1997™) were obtained from the American Type Culture Collection 
(ATCC). The human pancreatic stellate cell line EP1077 was established from pancreatic tumor tissue in our 
department. All cells were kept at 37 °C in a humidified 5%  CO2 atmosphere using DMEM culture medium sup-
plemented with 10% fetal bovine serum (Gibco) and 1% penicillin/streptomycin (Sigma-Aldrich).
Patient‑derived pancreas organoid (PDO) cultures. Establishment of organoid  cultures14,15 and 
determination of KRAS mutational  status16 was achieved as previously described. For passaging, Matrigel domes 
with organoids were disrupted from a 24-well plate and collected in 10 mL cold splitting medium. Splitting 
Medium for patient-derived pancreatic ductal organoids was prepared with Advanced DMEM/F-12 medium 
supplemented with 10 mM HEPES (Gibco) and 1 × GlutaMAX (Gibco). The supernatant was discarded after 
centrifugation (1200 rpm, 5 min, 4 °C) and the pellet was resuspended in 1 mL TrypLE Express (RT, Gibco) and 
incubated for 15 min at 35 °C at 180 rpm. Digestion was stopped by adding 10 mL cold splitting medium and fol-
lowed by centrifugation (1200 rpm, 5 min, 4 °C). The pellet was resuspended in ice-cold Matrigel (Corning) and 
plated at 1:2 ratio into a 24-well plate with 25 µL Matrigel for each dome. Organoid feeding medium was added 
after 15 min incubation at 37 °C. Feeding medium consisted of Wnt3a-conditioned medium (50% v/v) con-
taining 500 nM A83-01, 50 ng/mL mEGF, 100 ng/mL hFGF10, 0.01 µM Gastrin I, 1.25 mM N-Acetylcysteine, 
10 mM Nicotinamide, 1 × B-27 supplement and 1 × R-Spondin I-conditioned medium (10% v/v). Shortly before 
use 10.5 µM Rho-associated kinase (ROCK) inhibitor Y-27632 was added to the medium. Organoid feeding 
medium was changed every 2–3 days and cultures were split once every 7–10 days. All steps were performed 
on ice, unless indicated differently. For the present analyses organoids were cultured for 2–5 months; passage 
numbers used for experiments are documented in Table 2.
RNA‑isolation and quantitative PCR (qPCR) analysis. Matrigel domes were disrupted in 1 mL ice-
cold PBS for RNA-Isolation. Organoids were centrifuged (5300 rpm, 5 min, 4 °C) and the supernatant discarded. 
Pellets were resuspended in 500 µL cell recovery solution (Corning) and incubated for 60 min on ice. Finally, 
pellets were washed with 500 µL ice-cold PBS. After centrifugation (5300 rpm, 10 min, 4 °C), the supernatant 
was discarded and the organoid pellets were frozen at -80 °C until further analysis.
Total RNA was isolated from organoid cultures and cell cultures using the RNeasy Mini Kit (Qiagen) accord-
ing to manufacturer’s instructions. RNA concentration and purity was determined using a TECAN Reader infi-
nite M200. For cDNA synthesis, RevertAid First Strand cDNA Synthesis Kit (Thermo Fisher) was used according 
to manufacturer’s instructions and the cDNA was diluted to 3 ng/µL for qPCR analysis.
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qPCR was performed in triplicates and negative controls lacking cDNA were included. Each reaction con-
tained 9 ng of cDNA or noRT-control in a final volume of 10 µL, 5 µL Power SYBR Green PCR Master Mix 
(Applied Biosystems) and the primer’s concentration was 7.5 µM. The qPCR run on a LightCycler 480 Instrument 
denature II (Roche) and was as following: (1) hot start cycle at 95 °C for 10 min, (2) 40 cycles at 95 °C for 15 s 
and (3) annealing at 60 °C for 1 min. Relative gene expression of three independent experiments was normal-
ized to β-actin and calculated by the  2-ΔΔCt method compared to the mean value across all cell lines or to PDO 
pancreatitis control. The primer sequences were designed as follows:
NT5E fwd 5′-GAA GGC CTT TGA GCA TAG CG 3′; rev 5′-CGA CAC TTG GTG CAA AGA ACA-3’
AZU1 fwd 5′-GCG TGA CGA TAC TGC CAC T-3′; rev 5′-TCA CGT TGA CAA ACC TGG GA-3’
ATP6AP2 fwd 5′-GCC TAT ACC AGG AGA GCG GA-3′; rev 5′-CCG AGG ACG ATG AAA CAG GT-3’
IFNLR1 fwd 5′-CGT GTA CCT GAC ATG GCT CC-3′; rev 5′-TGG TTC CCG CAC ACT CTT C-3’
CTSO fwd 5′-ACA GCA TCA CTG CTC TAG TGG-3′; rev 5′-ACT CCC CAA GAA CTT CCC CA-3’
MICA fwd 5′-AGA ATC CGG CGT AGT CCT GAG-3; rev 5′-ATT CCG GGG ATA GAA GCT GGAA-3’
CDCP1 fwd 5′-GAA CTG CGG GGT CTC TAT CG-3′; rev 5′-CTC GTG GCA GAG CAA TCT CA-3’
TNFRSF12A fwd 5′-TTT TGG TCT GGA GAC GAT GCC-3′; rev 5′-TCA CTG GAT CAG CGC CAC AG-3’
MAEA Hs_MAEA_1_SG QuantiTect Primer Assay (Qiagen)
Immunocytofluorescence staining. Cells were seeded on glass cover slips in DMEM medium and cul-
tured for 48 h. Culture media was removed and cells were fixed with ice-cold methanol for 15 min at − 20 °C and 
washed with PBS. Fixed cells were permeabilized with 0.5% Triton X-100 (RT) for 5 min. Unspecific binding 
was blocked with 2% BSA for 30 min at RT and cells were incubated over night at 4 °C with primary antibod-
ies diluted in 2% BSA (rabbit-α-NT5E, Cell Signaling 1:75; rabbit-α-AZU1, LSBio, 1:250; rabbit-α-ATP6AP2, 
LSBio, 1:75; goat-α-MICA, R&D Systems, 1:250; mouse-α-MAEA, R&D Systems, 1:250). After washing with 
PBS, the cells were incubated for 60 min with the respective secondary antibodies (goat-α-rabbit Cy3, Thermo 
Fisher 1:250; monkey-α-goat Alexa 594, Abcam 1:500; goat-α-mouse Cy3, Invitrogen 1:250). After washing with 
PBS the cells were stained with DAPI (1:10.000 in aqua dest.) for 2 min. Afterwards, the coverslips were embed-
ded in Kaiser’s glycerol gelatine. Samples were analyzed with a fluorescence microscope (Olympus).
Immunohistochemistry (IHC) staining. For IHC staining, organoid-domes were fixed in the culture 
plate with 500 µL 4% paraformaldehyde (PFA) for 15 min. Removal of PFA was followed by embedding the 
domes in 1 mL 2% agarose gel. Samples were then dehydrated and embedded in paraffin, sectioned at 3 µm and 
placed on slides. The sections were deparaffinized using ROTIHistol (Roth) and rehydrated in an alcohol gradi-
ent. Antigen retrieval was performed in a pressure cooker for 15 min with 10 mM sodium citrate (pH 6.0 with 
0.05% Tween20). Endogenous peroxidase was quenched with 3%  H2O2 for 30 min, followed by three washing 
steps with TBS-T (pH 7.6, 0.05% Tween20). Non-specific background was blocked with 1% BSA/TBS-T for 
60 min. The primary antibodies were diluted in 1% BSA/TBS-T (rabbit-α-NT5E, Cell Signaling, 1:250; rabbit-
α-AZU1, LSBio, 1:1500; rabbit-α-ATP6AP2, LSBio, 1:1000; rabbit-α-MICA, Abcam, 1:1000; mouse-α-MAEA, 
R&D Systems, 1:50) and incubated at 4 °C overnight. Slides were washed three times in TBS-T and incubated 
with EnVision anti-rabbit- or anti-mouse-HRP (DAKO) for 60 min at RT. Slides were again washed three times 
in TBS-T. Immunoreactions were detected using DAB (1:50) as chromogen for 2 min, followed by a washing step 
in water. Finally, the slides were counterstained with Mayer’s hematoxylin (1:5 in aqua dest.) for 5 min, followed 
by incubation in warm water for 10 min. Slides were dehydrated with graded alcohols, cleared in Xylene and 
mounted using the ROTIHistokitt II (Roth).
Western Blot. Total protein extracts were prepared from PDAC cell lines PANC-1, MIA PaCa-2, HPAF-II 
and Capan-2 and the stellate cell line EP1077 by lysis in RIPA-buffer (50 nM Tris, 150 nM NaCl, 1% Nonidet 
P-40, 0.5% Sodium Deoxycholate, 1 mM EDTA, 0.1% SDS) supplemented with protease inhibitors (complete 
protease inhibitor cocktail, Roche). Protein concentrations were determined at 562 nm on the TECAN Reader 
infinite M200. Equal amounts of the respective cell lysates (20 μg total protein) were separated after denaturation 
(95 °C, 5 min) on a 12% SDS-PA gel (60 min, 150 V). Afterwards the gel was blotted in Towbin transfer buffer 
(20% methanol) onto a nitrocellulose membrane (120 min, 300 mA). The membrane was blocked with 5% milk 
powder (MP)/TBS-T for 60 min at RT. Overnight incubation with the primary antibodies was performed at 
4 °C with orbital shaking (NT5E (Cell Signaling, 1:2000 5% BSA/TBS-T), AZU1 (LSBio, 1:500 5% MP/TBS-T), 
ATP6AP2 (LSBio, 1:500 5% MP/TBS-T), MICA (Abcam, 1:1000 5% MP/TBS-T) and MAEA (R&D Systems, 
1:750 5% BSA/TBS-T)). The membrane was washed with TBS-T and subsequently incubated with horseradish 
peroxidase (HRP)-conjugated secondary antibodies (α-rabbit HRP, Cell Signaling; α-mouse HRP, Cell Signal-
ing) at a dilution of 1:5000 in 5% MP/TBS-T or 5% BSA/TBS-T for 90 min at RT on the shaker. The membrane 
was washed with TBS-T and the signal amplified with a chemiluminescent reagent (Thermo Fisher Scientific) 
before the membrane was developed using the BioRad ChemiDoc system. For loading control, the membrane 
was stripped with TBS-T for 60 min and incubated with the α-PDI antibody (Enzo Life Sciences, 1:1000) in 5% 
MP/TBS-T for 90 min at RT. The signal was again detected after incubation with HRP-conjugated secondary 
antibodies (α-rabbit HRP, Cell Signaling).
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Enzyme‑linked immunosorbent assay (ELISA). Levels of respective proteins were quantified with 
Human MICA ELISA Kit (LS-Bio, LS-F150), Human ATP6AP2 ELISA Kit (Aviva Systems Biology, OKEH04445), 
Human NT5E ELISA Kit (Biorbyt, orb385324) and Human AZU1 ELISA Kit (Biorbyt, orb390828). All incuba-
tions were performed in a closed chamber at room temperature and according to the manufacturer’s instruc-
tions. Wells were precoated with target specific antibodies. 100 μL of standard, blank and cell culture superna-
tants were added in duplicates and incubated for 150 min with constant shaking. The plate was then washed four 
times with washing buffer. 100 μL of detection antibody solution was added, followed by 60 min incubation with 
gentle shaking. The wells were emptied and washed four times with wash solution. HRP-Streptavidin solution 
(100 µL) was incubated for 45 min with constant shaking. Finally, 10 μL Tetramethylbenzidine (TMB) substrate 
was added and incubated for 30 min with constant shaking. The optical density was determined at 450 nm using 
the TECAN Reader Infinite M200 after addition of 50 μL Stop Solution.
Statistical analysis and software. Each experiment was performed at least three times independently, 
unless otherwise stated. All statistical evaluations were performed with the statistical software GraphPad® Prism 
version 8.4 or Microsoft® Excel 2016. Differences between the measured values in the ELISAs were investigated 
with one-way analysis of variance (ANOVA) followed by Tukey’s post-hoc test. Data obtained from organoid 
experiments was analyzed using Student’s t-test following testing for normal distribution based on Shapiro–
Wilk. The average values are given as mean value ± standard error of the mean (SEM). P-values of < 0.05 were 
considered statistically significant. Significances were shown with symbols (*p < 0.05; **p < 0.01; ***p < 0.001). 
Figures were created using GraphPad® Prism version 8.4 and Microsoft® Excel 2016 and PowerPoint 2016.
Results
Plasma samples show differences in protein levels between PDAC patients with early and 
late recurrence. In order to identify potential tumor biomarkers projecting early postoperative recurrence, 
pooled plasma samples from PDAC patients with different recurrence times after curatively intended pancreatic 
surgery were tested in a targeted proteome analysis approach using a plasma proteome array for 1012 proteins 
(Olink Bioscience, Uppsala, Sweden). Plasma from a total of 14 patients diagnosed with PDAC was collected 
just before and during surgery. Samples were pooled into three groups according to time until tumor recur-
rence: Five patients experienced a relapse within 6 months after resection (termed early recurrence), 4 patients 
had a relapse 6–12 months after resection (termed medium recurrence) and in 5 patients no tumor could be 
detected even 12 months after surgery (termed late recurrence). Clinicopathological patient characteristics are 
summarized in Table 1. The values for preoperative and intraoperative samples were summarized for the respec-
tive recurrence times, since only one single protein (GH2) showed an influence of the operation on expression 
level (data not shown). Twenty-three potential biomarker proteins were then selected for further analysis based 
on their at least twofold change in expression levels between early and late recurrence samples (Fig. 1). Interest-
ingly, for the majority of markers, the results for samples from patients with medium recurrence placed between 
those from patients with early and late recurrence. This however limited their comparative evaluation in both 
directions. We therefore decided to focus on the comparison only between early and late recurrence for the 
subsequent analyses. Eight of the 23 selected proteins demonstrated relatively higher abundance in plasma from 
patients with early recurrence compared to patients with late recurrence. Particularly relevant were MAEA and 
GIF, which showed 12-fold and fivefold higher concentrations respectively in patients with early recurrence. 
Fifteen proteins displayed lower abundance in plasma from patients with early recurrence. The protein levels for 
GH2 in patients with early recurrence were 33-fold lower compared to those in patients with late recurrence, 
with probable bias due to the above-mentioned observation. A fivefold to 11-fold decrease in early vs. late recur-
rence samples was observed for ATP6AP2, FOLR3 and CRX.
Expression analysis of potential biomarkers in established pancreatic cancer cell lines. To 
further validate our findings from patient plasma samples and to confirm a link to expression by PDAC cells, we 
analyzed mRNA expression of our 23 target genes in four established PDAC cell lines and one human pancre-
atic stellate cell line (PSC) as a control by qPCR. Nine of the 23 genes were expressed in all tested PDAC lines 
(Fig. 2A). We could observe that two of these genes, ATP6AP2 and TNFRSF12A, were expressed similarly and 
on low levels in all cell lines investigated. The other seven genes demonstrated differential expression across the 
four tumor cell lines. NT5E expression was found to be the highest in Capan-2, the same applied for MAEA, 
CDCP1 and CTSO. The expression of these markers in Capan-2 was 3- to 6-times higher than the mean value 
over all cell lines. Interestingly, other genes like AZU1 showed a very strong expression in PANC-1 followed 
by MiaPaCa-2, with a nearly 10- and 4-times higher expression respectively and poor signals in Capan-2 and 
HPAF-II. The opposite expression pattern was seen with MICA, demonstrating strong expression in Capan-2 
and HPAF-II, but weak signals in PANC-1 and MIAPaCa-2. The same was found for IFNLR1, but with 12.5 
times higher expression in HPAF-II. To discriminate expression by cancer cell lines and tumor stroma myofibro-
blasts, a pancreatic stellate cell line was also evaluated. Strong expression in PSC’s was only seen for MICA and 
CTSO, but not for the other genes (Fig. 2A).
Based on both, proteome array results and available literature on the relevance for pancreatic cancer, con-
firmatory analyses were performed for a selection of five genes and their corresponding proteins. We performed 
Western blot for AZU1, ATP6AP2, MAEA, MICA and NT5E with lysates obtained from the four PDAC cell lines 
and from our PSC cell line as control (Fig. 2B). MAEA showed the highest protein levels in Capan-2, followed 
by MIAPaCa-2 and PSC. Lower protein levels were detected in PANC-1 and HPAF-II. Consistent with mRNA 
levels, NT5E was present in all tumor cell lines and the stellate cell line with higher protein levels in Capan-2 
and MIAPaCa-2. AZU1 and ATP6AP2 were also expressed in all cell lines. Interestingly, no large differences in 
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protein expression could be observed in the Western blot while qPCR data indicates strong differences in AZU1 
expression. Protein levels for MICA were highest in HPAF-II, followed by PSC and Capan-2, in line with the 
observations on mRNA level (Fig. 2B). Immunofluorescence staining revealed that the MAEA protein was located 
in the nucleus of PANC-1 cells, whereas NT5E, ATP6AP2 and MICA were mainly localized in the cytoplasm; 
AZU1 was also localized in the cytoplasm but was predominantly found in vesicles (Fig. 2C).
To confirm the release of our target proteins from pancreatic cancer cells we evaluated the concentrations 
of candidate biomarkers in the cell culture supernatant (Fig. 2D). NT5E concentration was highest in Capan-2 
supernatant with lower concentrations in the other cell lines. AZU1 had the highest concentration in PANC-1 
supernatant, in line with the qPCR results. The other cell lines displayed lower values. Concentration of ATP6AP2 
was low in supernatants from all cell lines, except for HPAF-II, in spite of rather comparable expression across 
cell lines as determined by qPCR and Western blot. MICA was not detectable in PANC-1 and MIAPaCa-2 
supernatants, in consistency with the low levels on mRNA and whole cell lysate protein level.
PDO cultures confirm differential expression between early and late recurrence samples for 
selected biomarker candidates. As an additional step of validation for our findings from the proteome 
array and cell line analysis we established patient-derived organoid cultures (PDO), which can be generated 
directly from small PDAC tissue biopsies. This allowed modeling of individual tumor biology stratified by recur-
rence patterns in vitro. Organoids were retrospectively classified into two groups, according to the clinical course 
of corresponding patients. In total we analyzed seven pancreatic ductal organoid cultures of patients with known 
time points of tumor recurrence and clinical characteristics as given in Table 2. In 4 patients recurrence occurred 
within 6 months after resection (termed early recurrence; organoid lines E1-E4) and 3 patients experienced no 
relapse within the first 12 months after resection (termed late recurrence; organoid lines L1-L3). A ductal orga-
noid culture from a patient with chronic pancreatitis served as control (ctrl).
First, we assessed expression of the previously selected nine genes (as in Fig. 2A) by qPCR in organoid cultures 
of patients with early and late recurrence (Fig. 3). All of the markers tested were expressed by organoid lines, but 
in some cases with large differences. It was noticeable that E3 had low expression values for all markers, whereas 
many markers were highly expressed in E2. MAEA expression was quite consistently upregulated and showed up 
to 4-times higher expression in PDAC organoid lines compared to the single non-cancer control. It’s mean value 
appeared about 1.5-times higher in early recurrence compared with late recurrence organoids. Although not 
statistically significant in direct comparison, this observation was in accordance with the results from the plasma 
proteome array. In contrast to MAEA, levels of NT5E were much more variable. We saw high expression in two 
Table 1.  Clinicopathological data of patients who provided plasma samples analyzed in this study. d.n.a.: data 
not available; Gem: gemcitabine; Ab: nab-Paclitaxel; Cap: Capecitabine; Early: tumor recurrence within the first 
6 months after curatively intended resection; Medium: tumor recurrence within 6–12 months after resection; 
Late: no tumor recurrence even 12 months after resection; L: local recurrence, D: distant recurrence (hepatic/
pulmonal/peritoneal carcinomatosis); FU: follow-up.
Pooled sample Sex Age Entity Grading UICC Stage and R-Status Chemo-Tx Recurrence
EARLY
m 59y PDAC G2 pT3, pN0 (0/18). L0. V0. Pn1. R0 Adjuvant Gem + Cap Early (L + D)
f 81y PDAC G3 pT3, pN1 (2/20). L1. V0. Pn1. R1 None (postop complic.) Early (L)
f 55y PDAC G2 pT3, pN1 (2/17). pM1(hep). R0 loc Additive FOLFIRINOX Early (D)
f 74y PDAC G2 pT3, pN0 (0/14). L0. V0. Pn1. R0 Palliative Gem + Ab Early (L + D)
m 76y PDAC G3 pT3, pN2 (14/22). L1. V0. Pn1. R0 Palliative Gem + Ab Early (D)
MEDIUM
f 57y PDAC G3 pT3, pN2 (16/28). L1. V0. Pn1. R0 Adjuvant Gem (rec.) Medium (d.n.a.)
f 59y PDAC G3 pT3, pN2 (5/16). L1. V0. Pn1. R0 Adjuvant Gem Medium (L + D)
m 80y PDAC G3 pT3, pN1 (2/16). L1. V0. Pn1. R0 Adjuvant Gem Medium (L)
f 57y PDAC G2 pT3, pN2 (4/26). L1. V0. Pn1. R0 Adjuvant Gem Medium (L)
LATE
f 76y PDAC G2 pT2, pN1 (2/34). L1. V0. Pn0. R0 Adjuvant Gem Late (none at 44mo. of FU)
m 73y PDAC G2 pT3, pN0 (0/12). L0. V0. Pn1. R0 Adjuvant Gem + Cap Late (L at 33mo. of FU)
m 65y PDAC G2 pT3, pN1 (1/18). L0. V0. Pn1. R0 Adjuvant Gem + Cap Late (none at 48mo. of FU)
f 77y PDAC G2 pT3, pN0 (0/20). L0. V0. Pn1. R0 Adjuvant Gem Late (none at 57mo. of FU)
m 72y PDAC G2 pT3, pN0 (0/12). L0. V0. Pn1. R0 Adjuvant Gem Late (none at 56mo. of FU)
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Figure 1.  Normalized protein expression of plasma samples from PDAC patients with early (< 6 months), 
medium (6–12 months) and late (> 12 months) recurrence times. Pooled samples of 4–5 patients per recurrence 
time were analyzed. The samples were taken one day prior (preoperative sample) and directly after the surgical 
removal of the specimen. The values for preoperative and intraoperative sample were summarized for the 
respective recurrence times, since only GH2 showed an influence of the operation on the protein level. The 23 
proteins displayed showed at least a twofold change in protein expression between early and late recurrence. 
Left: Heat map of absolute values, displayed as log2. Right: Heat map of relative values as fold-change in 
comparison to late recurrence, set to 1, also displayed as log2.
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Figure 2.  Characterization of proteins in pancreatic cancer cell lines (PANC-1, MIA PaCa-2, Capan-2, 
HPAF-II) and pancreatic stellate cell line (PSC). (A) The mRNA levels were determined by qPCR for the genes 
MAEA, NT5E, AZU1, ATP6AP2, MICA, IFNLR1, CTSO, CDCP1 and TNFRSF12A. The expression level of 
each gene was normalized against β-actin. Data is presented as mean ± SEM (n = 3). (B) Expression of MAEA, 
NT5E, AZU1, ATP6AP2 and MICA was detected by Western blot analysis. Representative Western blots were 
selected from three independent experiments. PDI was included as a loading control. Full membrane blots 
are provided in Supplementary Figure S1. (C) Representative immunofluorescence images of PANC-1 cells 
stained for MAEA, NT5E, AZU1, ATP6AP2 and MICA (red). Nuclei are stained in blue with DAPI. (D) Protein 
concentrations of NT5E, AZU1, ATP6AP2 and MICA in cell culture supernatants were determined by sandwich 
ELISAs. For values outside the linear range, the value of the smallest standard as minimum or the value of the 
largest standard as maximum was used for presentation. The mean value ± SEM is given (n = 3 in duplicates). 
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patients with early recurrence (E2, E1) and low values for E3 and E4. These results might indicate an increased 
NT5E expression in a subgroup of early recurrence cases. AZU1 expression was increased in three PDAC orga-
noid cultures (E2, E4, L2) and at the same level as in the control in the other lines. In summary, elevated AZU1 
expression appears to be observable in a subgroup of cases, irrespective of the tumor recurrence time. CTSO 
expression was elevated in one out of three late recurrence samples but two out of four early recurrence samples. 
Overall analysis thus suggested a trend for higher expression levels in early recurrence than in late recurrence 
samples. Results for MICA transcription were heterogeneous, with higher and lower expression levels in samples 
from both recurrence groups. For ATP6AP2, IFNLR1, CDCP1 and TNFRSF12A expression we observed simi-
larly reduced levels in early and late recurrence PDAC organoids in comparison to the control sample (Fig. 3).
Next, to examine protein translation, immunohistochemistry for ATP6AP2, AZU1, MAEA, MICA and NT5E 
was performed on the PDO cultures. Semiquantitative analyses supported our observations from qPCR, yielding 
largely corresponding staining patterns. For presentation we selected one representative organoid culture from 
each recurrence time, E2 for early and L2 for late recurrence (Fig. 4). Of note, the organoids quite reliably reca-
pitulated primary tumor tissue; correlating immunohistochemistry sections of organoid source tissue biopsies 
are provided in Supplementary Fig. S2.
Discussion
In an exploratory analysis we here aimed at identifying potential plasma protein biomarker candidates for predic-
tion of early tumor recurrence after curatively intended PDAC resection. Following targeted plasma proteome 
analysis we were able to confirm expression and secretion of a number of candidates by established pancreatic 
cancer cell lines with correlation in representative patient-derived PDAC organoids.
Our initial analysis identified 23 proteins with differential abundance in the plasma of patients with early 
and late recurring pancreatic cancer following resection. We could confirm the transcription of nine genes by 
qPCR (for a summary of previously reported molecular implications and correlations with PDAC tumor dynam-
ics see Table 3) in four different established, commercially available pancreatic cancer cell lines and further 
analyzed ATP6AP2, AZU1, MICA and NT5E on the basis of available literature on relevance in PDAC. MAEA 
was analyzed for its meaningful differential expression levels in our plasma sample analysis. On protein level, 
expression of MAEA, NT5E and to a great extent of AZU1 and MICA but not of ATP6AP2 was confirmed in 
the PDAC cell lines.
NT5E is the coding gene for the ecto-5’-nucleotidase (CD73) which hydrolyzes extracellular AMP to 
 adenosine17. CD73-generated extracellular adenosine enhances tumor growth, angiogenesis and metastasis and 
suppresses antitumor immune  responses18. Increased NT5E expression has previously been associated with poor 
prognosis and correlated with tumor invasion and metastasis in PDAC and other solid  tumors17,19,20. In agree-
ment with these data we found that NT5E levels were elevated in the plasma of patients with early recurrence. 
We could also detect an elevation of NT5E expression in individual PDAC organoids established from tumors 
with early recurrence.
High MICA (MHC class I polypeptide-related sequence A) levels have been linked to favorable prognosis in 
 PDAC21. MICA is a MHC class I related molecule but not involved in peptide presentation. It rather functions 
as a stress-induced antigen and is recognized by activating NKG2D receptors on NK cells, γδ- and  CD8+-T-cells, 
resulting in cell lysis at high  expression22. In line with this we found lower MICA levels in plasma from patients 
with early recurrent tumors. Unfortunately, we could not detect or confirm a clear pattern of expression differ-
ences comparing organoid lines from tumors with early and late recurrence and non-tumor tissue.
Table 2.  Clinicopathological data of patients who provided tissue for patient-derived organoid cultures 
(PDO) used in this study. n.a.: not applicable; d.n.a.: data not available. *Neoadjuvant therapy w/ 3 cycles 
FOLFIRINOX and insufficient response; RT: radiotherapy; Gem: gemcitabine; Ab: nab-Paclitaxel; Cap: 
capecitabine; Early: tumor recurrence within the first 6 months after curatively intended resection; Late: no 
tumor recurrence even 12 months after resection; L: local recurrence, D: distant recurrence (hepatic/pulmonal/
peritoneal carcinomatosis); FU: follow-up.
Organoid ID (passage #) Sex Age Entity Grading UICC Stage and R-Status KRAS mutation Adjuv./Addit. Tx Recurrence
E1 (P15-P16) m 35y PDAC* G2 ypT3, pN1 (3/14). L0. V0. Pn1. R1 KRAS G12R Additive RT; Gem + Ab Early (L + D)
E2 (P14-P15) m 70y PDAC G2 pT3, pN2 (7/27). L1. V0. Pn1. R1 KRAS G12D Adjuvant Gem + Cap Early (D)
E3 (P18-P20) f 68y PDAC G2 pT3, pN2 (5/37). L1. V1. Pn1. R0 KRAS G12D None (postop complic.) Early (L + D)
E4 (P21-P22) f 60y PDAC G2 pT3, pN0 (0/7). L0. V1. Pn1. R0 KRAS G12D d.n.a Early (d.n.a.)
L1 (P15-P21) m 79y PDAC G3 pT3, pN2 (6/16). L1. V0. Pn1. R0 KRAS G12R Adjuvant Gem + Cap Late (L + D at 18mo. of FU)
L2 (P10-P21) m 73y PDAC G3 pT2, pN2 (4/22). L1. V0. Pn1. R0 KRAS G12D Adjuvant Gem + Cap Late (none at 24mo. of FU)
L3 (P6-P8) m 59y AdenoCa G2 pT2, pN1 (1/19). L1. V0. Pn0. R1 KRAS WT d.n.a Late (none at 12mo. of FU)
Ctrl (P10-P11) m 63y Chronic pancreatitis n.a n.a KRAS WT n.a n.a
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Figure 3.  Gene expression analysis of patient-derived PDAC organoid cultures. The mRNA levels in seven organoid cultures (late 
recurrence: L1, L2, L3/early recurrence: E1, E2, E3, E4) were determined by qPCR for the genes MAEA, NT5E, AZU1, ATP6AP2, 
MICA, IFNLR1, CTSO, CDCP1 and TNFRSF12A. A ductal organoid line from a chronic pancreatitis patient (ctrl) served as control. 
The expression level of each gene was normalized against β-actin. Data is presented as mean ± SEM (n = 3), except AZU1 for E4, L2, 
L3 (n = 1). For each gene of interest, graphs on the left depict results for individual organoid lines, and graphs on the right a merged 
analysis including statistics. Statistical evaluation was performed using Student’s t-test: *p < 0.05; **p < 0.01; ***p < 0.001.
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ATP6AP2 encodes the (Pro)renin receptor, which is reported to induce the proliferation of pancreatic cancer 
cells through Wnt/β-catenin  pathways23. In previous studies ATP6AP2 was reported to be overexpressed in many 
cancer types, including pancreatic  cancer23,24. In contrast, in our case ATP6AP2 levels were lower in blood from 
patients with early recurrence and its expression appeared to be somewhat lower in PDAC organoids compared 
Figure 4.  Immunohistochemistry staining of PDAC organoid cultures for MAEA, NT5E, AZU1, ATP6AP2 
and MICA. The same organoid cultures as in Fig. 3 were analyzed. Brown color represents a positive staining. 
Staining intensity was semi-quantitatively scored as: 0 (negative), 1 (weak), 2 (moderate), 3 (strong) and is 
shown in the bottom panels as stacked bar graphs. For representation we selected organoid culture L2 for late 
recurrence, E2 for early recurrence and the non-tumor chronic pancreatitis organoid line as control.
Table 3.  Summary of characteristics of potential biomarkers indicating early recurrence of PDAC following 
resection. PM: plasma membrane; OS: overall survival; DFS: disease-free survival.
Gene Localization Clinical relevance for PDAC Fold-change (early recurrence) References
ATP6AP2 PM, ER, Vesicles
Highly expressed in PDAC tissues and PDAC cell lines.
Essential for activation of Wnt/ ß-catenin signaling pathway in PDAC cells, promotes PDAC 
cell proliferation.
− 4.9 23,24
AZU1 Vesicles Detected in pancreatic juice of PDAC patients.  + 2.0 25
CDCP1 PM Represses epithelial phenotype of pancreatic cancer cells.High expression is correlated with poor prognosis in PDAC. − 2.5
33,34
CTSO Lysosome No published data. − 1.7 –
IFNLR1 Cytosol No published data. − 2.0 –
MAEA Nucleoplasm No published data.  + 11.7 –
MICA Cytosol, PM
MICA expression is an indicator of good prognosis in PDAC.
Elevated sMICA levels are associated with a poor survival in patients with PDAC.
Poorly differentiated PDAC show high sMICA expression.
− 2.4 21,35
NT5E Cytosol, PM
Overexpressed in many types of cancer.
High expression correlates with poor OS and DFS in solid tumors.
Upregulated in PDAC and correlated with poor prognosis.
 + 2.3 17,19,20
TNFRSF12A Cytosol, PM Elevated expression in pancreatic cancer cell lines. − 2.3 36
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to the non-cancer control. We were however not able to substantiate differences between early and late recur-
rence on the organoid level.
AZU1, which we found to be elevated in the plasma of patients with early recurrence, has previously been 
detected in the pancreatic juice of PDAC  patients25. The protein is called Azurocidin-1 or Heparin-binding pro-
tein and has antimicrobial activity and chemoattracts  monocytes26. It is also discussed as a potential biomarker 
for early diagnosis of  sepsis27. We found an elevated AZU1 expression only in some PDAC organoid cultures, but 
from both recurrence time groups. Its function in cancer is largely unknown, and based on our data its relevance 
for pancreatic cancer progression remains elusive.
Yet, one very promising protein appears to be MAEA. To date, the role of MAEA in cancer remains unclear 
and no previous studies in pancreatic cancer appear to exist. Even its precise biological function remains contro-
versial. It is reported to be part of the CTLH E3 ubiquitin-protein ligase complex, which promotes cell prolifera-
tion, and MAEA is especially required for the catalytic activity of the  complex28,29. One study describes that the 
CTLH complex in whole, consisting of eleven proteins, is overexpressed in some types of  cancer30. MAEA has 
also been found to mediate the attachment of erythroblasts to macrophages, which promotes terminal maturation 
and enucleation of erythroblasts, presumably by suppressing  apoptosis31. In non-erythroid cells MAEA partially 
co-localizes with actin in the nucleus and undergoes dynamic rearrangements in mitotic cells, suggesting involve-
ment in cytokinesis and cell  division32. In our experiments MAEA was perioperatively detected in the plasma of 
pancreatic cancer patients, especially of those with early tumor recurrence after resection. In comparison, the 
plasma abundance was remarkably lower in patients with medium and late recurring tumors. These results were 
confirmed by an observable tendency towards higher expression of MAEA on transcriptional and translational 
level in PDAC organoids of patients with early recurrence, compared with late recurrence. MAEA thus appears 
to be an interesting candidate for further evaluation.
Taken together, two potential plasma protein biomarker candidates may be further evaluated based on this 
study: first NT5E, which is of great interest for pancreatic cancer as elevated expression has been connected to a 
poor prognosis of patients, and second MAEA, which might be involved in cell proliferation and thereby linked 
to aggressive tumor biology.
The here presented work certainly allows only limited conclusions given the rather small sample size. Addi-
tionally, patient selection was not controlled for by balancing pathological examination results, thus differences 
in histological staging may have introduced selection bias. Next, the primary exploratory proteome analysis was 
performed only once, which might have resulted in a high rate of marker drop-out. And last, protein expres-
sion in organoids may be altered by the required specific culture conditions and by the lack of interaction with 
microenvironmental cell-types and cues. Thus, further confirmation in a larger cohort of patients and probably 
the generation and validation of a biomarker panel are required.
Yet, our data demonstrate—in a hypothesis generating approach—that identification of preoperative plasma 
protein biomarkers with potential to predict early recurrence after PDAC resections may be feasible. Preopera-
tive projection of late or early recurrence based on a simple blood draw would help to better stratify up-front 
resectable PDAC patients for neoadjuvant chemotherapy in an individualized approach.
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